Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

inflammatory conditions

- PMLiVE

J&J’s Caruso bullish on Remicade defence plans

Believes top-selling arthritis treatment will weather introduction of biosimilars in US market

- PMLiVE

FDA halts study of Teva and Regeneron’s pain drug fasinumab

Firms to redesign phase III trial excluding patients with advanced osteoarthritis after set back

Deal Watch September 2016

Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up

- PMLiVE

Merck sees €2bn from new launches by 2022

Expects to deliver total sales of €4bn with multiple sclerosis, fertility and cancer drugs portfolio

- PMLiVE

Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx

Releases phase II data from head-to-head study with Pfizer's Sutent

- PMLiVE

Pfizer to sell off Hospira’s infusions business – and its New York HQ

Infusion therapy specialist ICU Medical buys up unit in $1bn deal

- PMLiVE

Transformational technology

Big data, the cloud and the value of insights

- PMLiVE

Pfizer decides against long-discussed break-up

Says dividing its R&D and generics businesses would disrupt rather than create value

- PMLiVE

Medical Research Council launches disease compounds research library

Teams up with AZ, GSK, Janssen, Pfizer, Takeda and UCB

Deal Watch August 2016

Pfizer's hat trick as well as Sanofi, GlaxoSmithKline, Boehringer Ingelheim and more are featured in this month's round-up

- PMLiVE

Pfizer launches app to help patients manage depression

Hopes the Moodivator app will complement treatment and support care teams

- PMLiVE

A new era of collaboration

Looking at the factors driving this change and assessing the benefits

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links